Insider Selling: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP Sells 5,000 Shares of Stock

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP Amit Sachdev sold 5,000 shares of the stock in a transaction on Wednesday, January 8th. The shares were sold at an average price of $230.00, for a total value of $1,150,000.00. Following the sale, the executive vice president now owns 41,190 shares of the company’s stock, valued at approximately $9,473,700. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Amit Sachdev also recently made the following trade(s):

  • On Monday, December 9th, Amit Sachdev sold 5,000 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $225.00, for a total value of $1,125,000.00.
  • On Monday, November 25th, Amit Sachdev sold 5,000 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $220.00, for a total value of $1,100,000.00.
  • On Tuesday, November 19th, Amit Sachdev sold 5,000 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $215.00, for a total value of $1,075,000.00.
  • On Monday, November 4th, Amit Sachdev sold 4,097 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $200.34, for a total value of $820,792.98.
  • On Friday, October 25th, Amit Sachdev sold 4,311 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $197.89, for a total value of $853,103.79.
  • On Tuesday, October 22nd, Amit Sachdev sold 3,883 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $190.27, for a total value of $738,818.41.

NASDAQ:VRTX traded down $1.31 during trading hours on Friday, hitting $228.95. 1,017,303 shares of the stock traded hands, compared to its average volume of 1,281,115. The firm has a 50 day moving average price of $220.62 and a 200 day moving average price of $191.21. The company has a current ratio of 3.44, a quick ratio of 3.32 and a debt-to-equity ratio of 0.12. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $163.68 and a fifty-two week high of $233.26. The firm has a market cap of $59.42 billion, a price-to-earnings ratio of 80.90, a PEG ratio of 1.34 and a beta of 1.47.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Wednesday, October 30th. The pharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.87 by $0.36. Vertex Pharmaceuticals had a net margin of 59.24% and a return on equity of 20.33%. The company had revenue of $949.83 million for the quarter, compared to the consensus estimate of $942.90 million. During the same period in the previous year, the business earned $1.09 EPS. The company’s revenue was up 21.1% on a year-over-year basis. Research analysts predict that Vertex Pharmaceuticals Incorporated will post 3.72 EPS for the current year.

Large investors have recently made changes to their positions in the business. Carroll Financial Associates Inc. increased its stake in shares of Vertex Pharmaceuticals by 23.5% in the fourth quarter. Carroll Financial Associates Inc. now owns 263 shares of the pharmaceutical company’s stock worth $57,000 after acquiring an additional 50 shares during the last quarter. Municipal Employees Retirement System of Michigan increased its stake in shares of Vertex Pharmaceuticals by 0.9% in the third quarter. Municipal Employees Retirement System of Michigan now owns 6,430 shares of the pharmaceutical company’s stock worth $1,089,000 after acquiring an additional 60 shares during the last quarter. Cleararc Capital Inc. increased its stake in shares of Vertex Pharmaceuticals by 1.7% in the third quarter. Cleararc Capital Inc. now owns 3,870 shares of the pharmaceutical company’s stock worth $656,000 after acquiring an additional 64 shares during the last quarter. Quadrant Capital Group LLC increased its stake in shares of Vertex Pharmaceuticals by 3.6% in the third quarter. Quadrant Capital Group LLC now owns 1,877 shares of the pharmaceutical company’s stock worth $305,000 after acquiring an additional 65 shares during the last quarter. Finally, Integrated Wealth Concepts LLC increased its stake in shares of Vertex Pharmaceuticals by 3.9% in the third quarter. Integrated Wealth Concepts LLC now owns 1,776 shares of the pharmaceutical company’s stock worth $301,000 after acquiring an additional 66 shares during the last quarter. 94.85% of the stock is currently owned by institutional investors.

A number of equities research analysts have recently commented on VRTX shares. Piper Jaffray Companies increased their price objective on Vertex Pharmaceuticals from $247.00 to $284.00 and gave the company an “overweight” rating in a research report on Monday. Raymond James downgraded Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday, January 2nd. Credit Suisse Group upgraded Vertex Pharmaceuticals to a “buy” rating and set a $231.00 price objective for the company in a research report on Friday, December 13th. Citigroup increased their price objective on Vertex Pharmaceuticals from $205.00 to $225.00 and gave the company a “buy” rating in a research report on Tuesday, October 22nd. Finally, BidaskClub upgraded Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and twenty have issued a buy rating to the company. Vertex Pharmaceuticals presently has an average rating of “Buy” and an average target price of $228.54.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.

Featured Story: Range Trading

Insider Buying and Selling by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.